key: cord-0255693-ridc86hq authors: Kandasamy, Matheswaran; Gileadi, Uzi; Rijal, Pramila; Tan, Tiong Kit; Lee, Lian Ni; Chen, Jili; Prota, Gennaro; Zhang, Jing; Rabbitts, Terence; Townsend, Alain; Cerundolo, Vincenzo title: Recombinant single-cycle influenza virus as a new tool to augment antitumour immunity with immune checkpoint inhibitors date: 2021-08-01 journal: bioRxiv DOI: 10.1101/2021.07.31.454512 sha: 16ae5c865bde0d0b12f3bbf69e051505c0625051 doc_id: 255693 cord_uid: ridc86hq Virus-based tumour vaccines offer many advantages compared to other antigen delivering systems. They generate concerted innate and adaptive immune response, and robust CD8+T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (S-NY-ESO-1 FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1 specific CD8+T cell response in lungs and spleen that resulted in the regression of NY-ESO-1 expressing lung tumour and subcutaneous tumour respectively. Combined administration with anti PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen specific CD8+T cell response and protection against tumour development in combination with PD-1 blockade. The fight against cancer remains unfinished as it continues to be a major threat to human life. Tumour antigen specific strategies such as the dendritic cell (DC) vaccine 1 have been previously investigated to elicit antigen specific anti-tumour immunity. Such approaches yielded limited success because of the profound tumour suppressive environment . Recent successes of treatments with immune checkpoint inhibition are impressive but leave many patients unaffected. Hence, multiple approaches are warranted to reverse tumour immunosuppression and induce anti-tumour T cell responses. The generation of antitumor immunity together with the reversal of tumour immune suppression might be achieved by triggering innate immune receptors which have been evolved to detect pathogen-associated molecular patterns (PAMPs). Intrinsically immunogenic pathogens with potential pattern recognition receptor (PRR) agonistic functions can induce potent anti-tumour responses 2 and with the help of genetic engineering, the immunogenic pathogens can be exploited as vectors to deliver tumour associated antigens (TAA). Viruses are naturally immunogenic and represent an attractive vehicle for antigen delivery as several studies have shown that antigens expressed by virus are more immunogenic than soluble antigen administered with adjuvant 3, 4 . Moreover, viruses infect antigen-presenting cells (APCs) and express their transgenes [5] [6] [7] [8] [9] . The proinflammatory immune response induced by the virus infection enhanced the transgene or tumour antigen presentation which has led to not only an increase in the frequency of antigen-specific cytotoxic T cells but also their avidity to tumour antigen-expressing cancer cells 10 . Influenza A virus (IAV) is an interesting candidate for antigen delivery since IAV infection elicits a strong antigen specific CTL response. We developed previously a pseudotyped replication deficient influenza A/Puerto Rico/8/34 (PR8) virus in which the HA signal sequence was inactivated (S-FLU) 11 ; this virus can replicate only in the cell line expressing HA which provides the HA protein on pseudotyped virus particles for their binding to cells and importantly, the HA expressed by the cell line can be derived from any virus subtype. Experimental infection with S-FLU virus has shown a robust CTL response but in the absence of neutralizing antibodies 11 . Here, we generated a recombinant S-FLU virus expressing NY-ESO-1(New York oesophageal squamous cell carcinoma 1) and evaluated its immunogenicity and therapeutic efficacy in preclinical mouse models. NY-ESO-1 is a wellknown cancer-testis antigen (CTA). Its expression is normally restricted in germ cells, but it is highly dysregulated in some malignant cells 12 . Given the immune-privileged nature of germline cells, NY-ESO-1 may be therapeutically targeted without substantial risk of immune related off-targeted effects. We found that intranasal or intramuscular immunization with NY-ESO-1 S-FLU virus elicits a robust NY-ESO-1 specific CTL response and suppresses the NY-ESO-1 expressing tumour development and spontaneous metastasis. Moreover, with anti PD1 antibody co-administration, NY-ESO-1 S-FLU virus immunization displays an enhanced tumour reduction. We generated S-FLU virus to express NY-ESO-1 by replacing the coding region of HA with NY-ESO-1 expressing sequence as described previously 11 (Fig.1A left) . Three positive S-FLU clones were identified ( Figure 1A specific CTL response in HHD (9.80±1.5%) and BALB/c mice (11.04±1.0%) albeit to a lesser magnitude than the CTL responses against the immunodominant FLU epitopes M1 and NP ( 30.14±3.5% and 14.82±3.6%, respectively). Intranasal infection with NY-ESO-1 S-FLU virus also induces NY-ESO-1 specific CTL response in spleen (Supplementary figure 4) . The effector function of the NY-ESO-1 specific T cells was further investigated with a in vivo killing assay. Results showed a strong NY-ESO-1 (157-165) specific cytotoxic effect in spleens of NY-ESO-1 S-FLU infected mice compared to the control . To investigate the effectiveness of NY-ESO-1 S-FLU virus against tumour challenge, we used syngeneic 4T1 metastatic breast carcinoma (MBC) tumour model. 4T1 cells generate primary tumours and spontaneously metastasize to dLNs, lungs, spleen, liver etc. following syngeneic transplantation in immunocompetent BALB/c mice and simulates stage IV of human breast cancer progression. We tested NY-ESO-1 S-FLU virus antitumor effect in the following settings: (1) prophylactic (2) Immunization with NY-ESO-1 S-FLU virus significantly reduced the number of nodules in lungs and interestingly, a single infection with NY-ESO-1 S-FLU was sufficient to give significant protection against tumour challenge (Fig 2A) . For the therapeutic model, mice were intravenously injected with 4T1-NY-ESO-1 cells followed by intranasal infection with NY-ESO-1 S-FLU or control GFP S-FLU and generally a higher number of tumour nodules developed in therapeutic setting than prophylactic model (~30 to 40%). Nonetheless, two sequential infections with NY-ESO-1 S-FLU virus significantly reduced the number of tumour nodules in lungs ( Fig 2B) . In the spontaneous tumour metastasis model, mice were subcutaneously injected with 4T1-NY-ESO-1 cells and subsequently infected intranasally with 1 or 2 doses of NY-ESO-1 S-FLU or GFP S-FLU or remained naive. On day 27, mice were euthanized and lungs were digested with collagenase, and dissociated cells were subjected to clonogenic assays in culture ( Fig 2C) . Primary tumour displayed spontaneous metastasis to lungs and mice that received two sequential infections with NY-ESO-1 S-FLU virus showed fewer colonies (421±325) (p<0.05) than any of the other treatments: no infection (29814±30716) two sequential infection with control GFP S-FLU virus (8900 ± 9215) or single infection with NY-ESO-1 S-FLU virus (9300±6916) ( Figure 2C ). Despite inducing a strong CD8 + T cell response in lungs, intranasal infection did not elicit a high CTL response in spleen ( Supplementary Fig 4) . Furthermore, it failed to protect mice from subcutaneous tumour challenge with NY-ESO-1 expressing 4T1 cells (Fig 3A) . A strong systemic immune response coordinated across tissues is required for tumour eradication 13 . Previously, intramuscular immunization (i.m) with recombinant adenoviralvectored vaccine has shown generation of CTL responses in multiple mucosal sites 14 . In order to analyse whether the i.m. route of infection with NY-ESO-1 S-FLU virus would generate a better systemic immune response, BALB/c mice were infected intranasally or intramuscularly with NY-ESO-1 S-FLU virus, and NP or NY-ESO-1 specific CD8 + T cell responses in peripheral blood, lung and spleen were examined by tetramer staining on day 10 post infection ( Fig 3B) . In lungs, intranasal infection induced a significantly higher NP (p<0.01) and NY-ESO-1 (p<0.05) specific CD8 + T cell response compared with intramuscular injection. In the blood and spleen, intramuscular infection induced stronger NP (p<0.01) and NY-ESO-1 (p<0.01) specific CTL responses than intranasal infection ( Figure 3B ). Similarly, an increased frequency of Flu M1 or NY-ESO-1 specific IFNg ( single producer), or IFNg and TNFa (double producer) or IFNg, TNFa and IL2 producing CD8 + T cells (triple producers) was observed in HHD mice spleen following intramuscular infection ( Figure 3C ) and conversely a higher frequency of flu M1 or NY-ESO-1 specific IFNg or IFNg and TNFa producing CD8 + T cells were detected in HHD mice lungs following intranasal infection ( Figure 3C ). Moreover, intranasal infection and intramuscular infection resulted in an accumulation of higher number of total Flu M1 / NY-ESO-1 specific CD8 + T cells in lungs and spleen respectively (Supplementary Fig 5) . The reciprocal distribution of antigen specific CD8 + T cells in lungs and spleen in post intranasal infection indicates that the effector T cells are mostly retained in lungs following intranasal infection. Activated antigen specific CD8 + T cells have been known to persist following recovery from respiratory virus infection and Very Late Antigen 1 (VLA-1; a1b1 integrin) has been implicated in the retention of T cells [15] [16] [17] . We therefore investigated whether the intranasal or intramuscular infection with NY- and (p<0.01 on day 26 and 28) which was concomitant with significantly higher infiltration of NY-ESO-1 specific CD8 + T cells in TIL (p<0.01) ( Figure 6A ) whereas, the mice infected via the intranasal route did not show any difference in tumour size ( Figure 6A ). NY-ESO-1 specific CTLs that infiltrate the tumour express a higher level of PD1. We also investigated the distribution of NY-ESO-1 specific CD8 + T cells in lungs and spleen and strikingly a higher number of NY-ESO-1 specific CD8 + T cells still accumulated in lungs in intranasally infected mice. However, there was no difference in the distribution of NY-ESO-1 specific CD8 + T cells in spleen of intranasally(172±123/10 6 splenocytes) or intramuscularly (154±142/10 6 splenocytes) infected mice ( Figure 6B ). To determine whether the infection through different routes would induce a diverse protection against spontaneous metastasis, from a primary subcutaneous tumour to the lungs, mice with 4T1-NY-ESO-1 established subcutaneous tumour were intramuscularly or intranasally administered with NY-ESO-1 S-FLU virus. At humane end point, mice were euthanized and lung or spleen homogenates were tested in clonogenic assay. In clonogenic assay, the number of colonies in lungs following intranasal or intramuscular infection were not significantly different from each other but lower than the mice with no infection (p<0.001) ( Figure 6C ). However, the impaired metastases in spleen was only observed in intramuscularly infected mice as depicted in Figure 6C . Figure 7B ). We observed that cytotoxic T cells infiltrated to the tumour displayed a higher expression level of PD1 ( Figure Next, we investigated whether the combined treatment of anti PD1 antibody and NY- to lungs. As depicted in Figure 8C , anti PD1 antibody monotherapy showed a reduced tumour metastasis to lungs and notably, in combined therapy with NY-ESO-1 S-FLU virus infection it demonstrated a significantly higher reduction in tumour metastasis (p<0.05). The major challenge for the development of tumour vaccines is identifying the delivery system that is capable of inducing safer and more efficient T cell responses. Recombinant In contrast, intramuscular injection with NY-ESO-1 S-FLU virus reduced primary tumour burden with decreased spontaneous tumour metastasis to lungs and spleen ( Figure 6C ). Intriguingly, primary tumour was highly infiltrated with antigen specific CD8 + T cells but not in lungs or spleens which suggests that decreased metastasis was likely due to primary tumour regression. As Single cell preparation from lungs was prepared as described before 52 and FMOs were used as control. For tumour model, 4T1 metastatic breast carcinoma -syngeneic mouse model has been used as described before 53 Cancer immunotherapy via dendritic cells Pattern recognition receptors: immune targets to enhance cancer immunotherapy Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus Induction of higher-avidity human CTLs by vectormediated enhanced costimulation of antigen-presenting cells Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives Systemic Immunity Is Required for Effective Cancer Immunotherapy Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model High avidity antigen-specific CTL identified by CD8-independent tetramer staining Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide Rescue of influenza A virus from recombinant DNA A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector RIG-I Signaling Is Critical for Efficient Polyfunctional T Cell Responses during Influenza Virus Infection Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis Oral administration of 3,3'-diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice Gating strategy for flow cytometric analysis of lung tissue resident memory T cells.